LexaGene Holdings Inc.
LXXGF · OTC
2/28/2022 | 2/28/2021 | 2/29/2020 | 2/28/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.40 | 0.67 | 0.09 | -0.02 |
| FCF Yield | -35.02% | -41.26% | -36.04% | -45.19% |
| EV / EBITDA | -2.40 | -1.51 | -2.18 | -1.58 |
| Quality | ||||
| ROIC | -139.24% | -78.66% | -128.21% | -601.06% |
| Gross Margin | -621.40% | -173.76% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.91 | 0.91 | 0.72 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -6.05% | -55.34% | 4.46% | -41.60% |
| Safety | ||||
| Net Debt / EBITDA | 0.35 | 0.86 | 0.18 | 0.08 |
| Interest Coverage | -150.10 | -131.33 | -72.89 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.39 | 0.15 | 0.00 | 0.00 |
| Cash Conversion Cycle | 1,007.80 | 2,723.06 | 0.00 | 0.00 |